Top Markets
#1 pippin pippin +20.01%
#2 City Boy City Boy +16.21%
#3 TRIA TRIA +15.95%
#4 Osaka Protocol Osaka Protocol +14.42%
#5 River Pts River Pts +13.00%
#6 Aria.AI Aria.AI +12.42%
#7 Infinity Ground Infinity Ground +11.45%
#8 Janction Janction +10.91%
#9 Strategic Oil Supply Strategic Oil Supply +9.88%
#10 Orochi Network Orochi Network +9.87%
Coin of the day
pippin pippin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Classifica tra le azioni #98
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Prezzo delle azioni
$37.45
Capitalizzazione di mercato
$166.43B
Variazione (1 giorno)
-2.55%
Variazione (1 anno)
-53.09%
Paese
DK
Scambia Novo Nordisk A/S (NVO)

Categoria

Healthcare
Rapporto P/S per Novo Nordisk A/S (NVO)
Rapporto P/S al January 2026 TTM: 5.21
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Novo Nordisk A/S, il rapporto P/S attuale (TTM) è 5.21. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Novo Nordisk A/S da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 89.90%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 3.60%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 17.70%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -41.63%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.90 147.31%
NL